TDC
AMRI

Thompson Davis & Co’s Albany Molecular Research Inc AMRI Stock Holding History

Thompson Davis & Co’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-11,700
Closed -$235K – 1313
2014
Q2 		$235K Buy
+11,700
New +$198K 0.34% 76

Other funds holding AMRI

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Thompson Davis & Co's AMRI Position: Q3 2014 in Review

Thompson Davis & Co sold out of Albany Molecular Research Inc (AMRI) in Q3 2014, closing a stake of 11,700 shares — an estimated $235K sold.

Thompson Davis & Co first reported a position in AMRI in Q2 2014 and held it in 1 quarter. The position peaked at $235K in Q2 2014. 143 funds tracked by Wall St. Rank hold AMRI as of Q3 2014.

  • Thompson Davis & Co reported no remaining Albany Molecular Research Inc position as of Q3 2014 after selling out during the quarter.
  • Thompson Davis & Co sold 11,700 Albany Molecular Research Inc shares in Q3 2014, an estimated $235K.
  • Thompson Davis & Co first reported a position in Albany Molecular Research Inc in Q2 2014 and held it in 1 quarter.
  • Thompson Davis & Co's Albany Molecular Research Inc position peaked at $235K in Q2 2014.
  • 143 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2014.

Based on Thompson Davis & Co's 13F filing for Q3 2014, filed 4 Nov 2014.